Intelligent Liver Function Testing:Working Smarter to Improve Patient Outcomes in Liver Disease by Macpherson, Iain et al.
                                                                    
University of Dundee
Intelligent Liver Function Testing
Macpherson, Iain; Nobes, Jennifer H.; Dow, Eleanor; Furrie, Elizabeth; Miller, Michael H.;
Robinson, Emma M.
Published in:
Journal of Applied Laboratory Medicine
DOI:
10.1093/jalm/jfaa109
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Macpherson, I., Nobes, J. H., Dow, E., Furrie, E., Miller, M. H., Robinson, E. M., & Dillon, J. F. (2020). Intelligent
Liver Function Testing: Working Smarter to Improve Patient Outcomes in Liver Disease. Journal of Applied
Laboratory Medicine, 5(5), 1090-1100. https://doi.org/10.1093/jalm/jfaa109
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 05. Oct. 2020
Intelligent Liver Function Testing: Working
Smarter to Improve Patient Outcomes in Liver
Disease
Iain Macpherson,a,† Jennifer H. Nobes,b,† Eleanor Dow,b Elizabeth Furrie,b Michael H. Miller,c
Emma M. Robinson,c and John F. Dillona,*
Chronic liver disease (CLD) is a significant health problem affecting millions of people worldwide. In Scotland, CLD
is a major cause of premature mortality. Liver function tests (LFTs) are a panel of frequently requested blood tests
which may indicate liver disease. However, LFTs commonly contain at least one abnormal result, and abnormali-
ties are rarely investigated to the extent recommended by national guidelines. The intelligent Liver Function
Testing (iLFT) pathway is a novel, automated system designed to improve early diagnosis of liver disease. Initial ab-
normal LFT results trigger a cascade of reflexive testing to help identify the cause of any liver
dysfunction. Algorithms combine these results with demographic and clinical data (such as patient age, body
mass index, and alcohol intake) and fibrosis estimates to produce an electronic diagnosis and management plan.
The pilot trial demonstrated that iLFT increased diagnosis of liver disease whilst remaining cost-effective. As such,
iLFT has been fully operational across our region (NHS Tayside, Scotland) since August 2018. In the first year, iLFT
generated over 2000 diagnoses from 1824 patient samples with an abnormality in the initial LFTs. The majority of
these patients could be safely managed in primary care. iLFT allows maximal value to be obtained from liver blood
tests across biochemistry, virology, immunology, and hematology with only minor changes to working practices.
‘Intelligent’, algorithm-led testing pathways break down the barrier between clinical and laboratory medicine and
offer solutions to many of the challenges experienced in modern healthcare systems.
INTRODUCTION
The incidence and prevalence of chronic liver
disease (CLD) has been rising continuously over
the past few decades. Globally, liver disease
results in approximately 2 million deaths per year,
as a result of both liver cirrhosis (around 1 million)
and viral hepatitis and hepatocellular carcinoma
(HCC) (around 1 million) (1). Cirrhosis and liver can-
cer together accounted for 3.5% of all worldwide
mortality in 2018, compared with 3% in 2000. This
approximation is likely a significant underestimate,
given the lack of accurate mortality information in
many developing countries, including those in
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which there is a significant burden of viral
hepatitis-related deaths (1, 2).
Worldwide, liver disease risk and prevalence
varies with gender, ethnicity, and socio-economic
status. Latin America & Caribbean and Middle
East & North Africa are the regions with the high-
est percentage of deaths due to liver disease, and
the absolute number of deaths is highest in South
Asia and East Asia & Pacific (3).
The Scottish Public Health Observatory
(ScotPHO) estimates that liver disease accounted
for 16.3 deaths per 100 000 population in
Scotland in 2018 (4). Liver disease is the leading
cause of death in the 35–49 age group, and the
third leading cause of death in individuals under
65 years of age (5). In addition, deaths from HCC
have risen by two-thirds in the past 10 years, now
ranking as the 9th most common cancer death,
and occur almost exclusively in patients with
chronic liver disease.
The three most common causes of liver disease
in the western world and industrialized countries
are nonalcoholic fatty liver disease (NAFLD),
alcohol-related liver disease (ARLD), and viral hep-
atitis. These three etiologies account for 90% of
chronic liver disease. All three are preventable,
and chronic hepatitis C is now curable. Globally,
this pattern varies. For example, in China and
other Asian countries, hepatitis B virus remains
among the leading causes of death (6).
It is estimated that around a third of adults in
the UK have the early stages of NAFLD. Therefore,
diagnosing liver disease earlier could provide a
window of opportunity to prevent the progression
to fibrosis and cirrhosis, and thus reduce the cur-
rent and future burden on healthcare systems (5).
Liver Function Tests
The primary method of screening for liver dis-
ease is by analyzing a panel of blood markers re-
ferred to as liver function tests (LFTs). Such a
panel will typically include liver enzymes such as
alanine aminotransferase (ALT) and/or aspartate
aminotransferase (AST), markers of hepatocyte in-
jury; bilirubin, a marker of parenchymal liver dis-
ease or biliary obstruction; and alkaline
phosphatase (ALP), which can be a marker of bili-
ary disease and cholestasis, but which is also pro-
duced by bone, intestine, and placenta. As well as
NAFLD, ARLD, and viral hepatitis, there are a num-
ber of other causes of elevated (abnormal) LFTs,
including autoimmune illnesses, biliary diseases,
systemic illness, drug reactions, and infective hep-
atitis. The etiology of liver disease can be identified
by a further cascade of specific blood tests known
as a serological liver screen. The presence or ab-
sence of liver fibrosis or cirrhosis can be assessed
using various noninvasive scoring systems [e.g.,
NAFLD fibrosis score and Fibrosis-4 (FIB-4) index]
or the use of transient elastography, but the gold
standard of diagnosis is a liver biopsy.
The number of LFTs requested in primary care
has risen dramatically in recent years, almost dou-
bling between 2002 and 2010 in the UK (7).
Around 20% of such LFTs have at least one ele-
vated marker (8). However, patients continue to
present to liver clinics and acute medical admis-
sion units with end stage liver disease, even in
cases in which the abnormal LFTs have been pre-
sent for a number of years, suggesting there is a
window for intervention to prevent progression
from early liver disease to chronic liver disease
that is being missed.
The Abnormal Liver Function Investigations
Evaluation (ALFIE) study from Tayside in Scotland
examined the consequences of incidental abnor-
mal LFTs in primary care between 1989 and 2003.
This study examined 95 977 patients who had
LFTs checked a total of 364 194 times. 21.7% of
patients had at least one abnormal liver enzyme,
and 1090 (1.14%) went on to develop chronic liver
disease within the timeframe of follow up (median
3.7 years) (8).
Birmingham and Lambeth Liver Evaluation
Testing Strategies (BALLETS) was a prospective
iLFT: intelligent Liver Function Testing SPECIAL REPORT
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study of patients with incidentally abnormal LFTs
in primary care (7). 1118 patients with abnormal
LFTs were followed up by way of a full serological
liver screen and ultrasound scan, as well as re-
cording their BMI (body mass index), weekly alco-
hol intake, and features of the metabolic
syndrome. NAFLD accounted for 26.4% of cases
with abnormal LFTs, and alcohol-related liver dis-
ease accounted for 25.3% of cases. Of the NAFLD
cases, 7.6% of patients had a high NAFLD Fibrosis
Score (NFS), indicating a likelihood of having ad-
vanced fibrosis or cirrhosis, and a further 35.2% of
patients had an indeterminate NFS, which recom-
mends further disease assessment in secondary
care (9). This study, alongside the ALFIE study,
indicates there is a significant number of patients
with chronic liver disease with no clinical signs who
could easily be identified at opportune moments.
ALT Upper Limit of Normal
In the ALFIE study, elevated transaminases (ALT
and/or AST) were associated with a diagnosis of
liver disease (8). However, the value of the upper
limit of normal (ULN) of ALT is subject to much de-
bate. The value is known to be affected by BMI
and age, validated in a study from Korea involving
over 1000 potential liver donors, which proposed
a ULN of 33U/L for men and 25U/L for women
(10). A European study involving 6835 blood
donors with normal BMI and no history of liver
disease identified an ULN of 30U/L for men and
19U/L for women (11), while an American study as
part of the National Health and Nutrition
Examination Survey (NHANES) between 1999–
2002 and 2005–2008 identified 29U/L for men
and 22U/L for women (12). Despite this, many lab-
oratories continue to routinely use significantly
higher ULN for ALT, usually 55U/L, without dis-
crimination between males and females. Using a
lower ALT may allow the earlier detection of
chronic liver disease, but it is unclear how this
would impact service delivery. In addition, it is
unclear if those with an ALT value of <55U/L
would require any intervention from healthcare
services, and so detection of an ’abnormality‘may
not add any clinically relevant information.
Primary Care Management of Abnormal LFTs
and the Introduction of the ELF Test
The management of abnormal LFTs by general
practitioners (GPs) is variable, despite the pres-
ence of national guidelines (13). Some abnormali-
ties are ignored, some patients undergo extensive
investigation, and some are referred to secondary
care. Such guidelines recommend different path-
ways based on the pattern of LFT abnormality, in-
cluding the drawing of various further blood
samples, calculation of noninvasive fibrosis scores,
and ultrasound imaging. Liver biopsy is defined as
the gold standard in the diagnosis of chronic liver
disease. However, it is expensive and has nota-
ble intra-observer variability (14). In addition,
Bravo et al. reported a hospitalization rate of up
to 1%–3% following percutaneous liver biopsy
with complications such as pain, vasovagal hypo-
tension, and less commonly, bleeding, sepsis,
and injury to surrounding organs (15). There is
also a small but significant risk of death; a large
study (n¼ 61 187) in the UK found the 7-day all-
cause mortality following liver biopsy to be 0.2%,
and the mortality directly related to the biopsy
procedure to be 0.01% (16). On account of this,
several noninvasive approaches to diagnose or
exclude advanced liver disease confidently have
been suggested.
The Enhanced Liver Fibrosis (ELF) score is a
blood test measuring three molecules—
hyaluronic acid, procollagen III amino-terminal
peptide, and tissue inhibitor of matrix metallopro-
teinase 1—involved in the metabolism of the liver
matrix. Elevated serum levels of these analytes
represent increased turnover of the extracellular
matrix and have been shown to correlate with var-
ious stages of liver fibrosis and cirrhosis (17). ELF
has been incorporated into the National Institute
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for Health and Care Excellence (NICE) guidelines
for the diagnosis of NAFLD (18). Higher scores are
associated with increased risk of liver-associated
adverse events such as decompensated chronic
liver disease and liver-related mortality (19).
Despite featuring in several sets of clinical guide-
lines, including those published by NICE and the
British Society of Gastroenterology (13, 18), the
ELF test is not routinely used in clinical practice
and indeed is limited to very few centers in the
United Kingdom. However, it appears to carry the
potential to provide a reliable marker of liver fibro-
sis and could eliminate the need for transient
elastography (which requires a secondary care
clinic appointment) or liver biopsy.
The ALFIE study found that 50% of patients
with abnormal LFTs underwent no further investi-
gative testing (8), and the BALLETS study found a
significant number of patients with abnormal LFTs
were at risk of advanced fibrosis and/or cirrhosis
(7). The workload on primary care is already sub-
stantial, and, despite clear guidelines for the man-
agement of abnormal LFTs (13), patients in whom
lifestyle interventions can make a difference go
undiagnosed. As a result, an automated, real-time
diagnostic tool—intelligent liver function testing
(iLFT)—was developed to diagnose liver disease
earlier and to provide management plans for GPs.
The aim of iLFT was to improve the diagnosis of
liver disease. Referrers (GPs) provide information
on BMI, the presence or absence of diabetes mel-
litus, and alcohol intake. In the case of any abnor-
mality in initial LFTs, iLFT would automatically
cascade into performing all of the recommended
blood tests indicated in guidelines, such as viral
serology, biochemistry testing, and immunology
serology. The results are combined with the infor-
mation provided by the GP and noninvasive fibro-
sis scoring systems to provide an automated, real-
time diagnosis. This diagnosis, with an associated
management plan (including whether the patient
requires specialist review), would be communi-
cated back to the GP.
DEVELOPMENT OF THE ILFT PATHWAY
Minimum Diagnostic Criteria
The initial development phase of the iLFT path-
way required formulation of minimum diagnostic
criteria for liver disease of various etiologies.
These criteria were created by an expert group of
hepatologists using Delphi methodology, with the
aim to produce an algorithm which would allow
patients to be stratified into three groups:
1) patients with early liver disease who can safely
be managed in primary care (such as patients with
uncomplicated NAFLD or ARLD); 2) patients in
whom the diagnosis is unclear, but liver screen
and fibrosis markers do not indicate liver disease
and there is no evidence of fibrosis; and 3) patients
with advanced liver disease or a liver diagnosis re-
quiring specialist hepatology input (for example,
any case of autoimmune hepatitis, or ARLD with
evidence of fibrosis/cirrhosis). Patients could
therefore be efficiently triaged, with groups 1 and
2 remaining in primary care for follow-up, and
group 3 receiving a recommendation of specialist
liver service referral (20).
With the vision of iLFT in mind, the only data
available to the hepatologists were limited patient
demographics and characteristics (patient age,
BMI, alcohol intake, and presence of metabolic
syndrome), results of a predefined liver etiology
screen, and calculated fibrosis scores (FIB-4 index
and NFS). The criteria were designed to ‘fail safe’,
with indeterminate fibrosis scores or presence of
autoantibodies triggering referral to secondary
care.
Validation of Diagnostic Criteria
The criteria were validated by comparing the
suggested diagnosis and referral recommenda-
tion (primary versus secondary care) using the
minimum diagnostic criteria against the ‘gold
standard’ opinion of an expert hepatologist who
had reviewed the patient in an outpatient clinic.
iLFT: intelligent Liver Function Testing SPECIAL REPORT
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The study population comprised 323 patients
who had been reviewed in liver clinics in 3 Scottish
tertiary referral hospitals. Referral recommenda-
tion agreement between the criteria and expert
opinion was seen in 91.3% of cases, and 23 of the
28 incorrect referral recommendations ‘failed safe’
to secondary care. Diagnostic agreement was
seen in 82.4% of cases. Of the 323 patients, all of
whom had been seen in secondary care as per
current practice, over a third could have been fol-
lowed up safely in primary care without being
seen in the liver clinic (20).
Laboratory Automation, Reconfiguration,
and IT Programming
Following development of the minimum diag-
nostic criteria, the next challenge was to employ
the existing functionality within our automated
laboratory system to allow these criteria to be ap-
plied in real-time as assay results were generated.
The Ninewells Blood Sciences Core Laboratory
had undergone a significant upgrade in 2012 with
the installation of AptioVR Automation technology
(Siemens Healthcare Diagnostics Inc.). The hema-
tology, clinical chemistry, and immunoassay sys-
tems were therefore linked by the track to various
other units including the input/output, centrifuga-
tion, and refrigerated storage modules. This func-
tionality was already utilized routinely by
aematology and biochemistry for reflex, reflective
and add-on testing, but for iLFT required virology
to move from batched testing of hepatitis serology
to real-time flow analysis.
iLFT required reprogramming of both the order
communications software and Laboratory
Information Management System (LIMS).
Electronic requesting via the order communica-
tions software [Sunquest ICE v7.0.5 (Sunquest
Information Systems)] is key to the function of
iLFT as it allows transfer of clinical information
(alcohol intake, BMI, and presence of metabolic
syndrome) into the LIMS in such a way that it can
be manipulated as data. Additionally, patient
demographics such as age can be extracted auto-
matically for use in the algorithms and calculated
fibrosis scores, reducing the required data input
from the requesting clinician. The order communi-
cations system prompts the requestor to take 3
blood samples—2 serum separator tubes for
biochemistry, virology, and immunology analyses,
and a potassium-ethylenediaminetetraacetic acid
(K-EDTA) sample for hematology analysis.
On arrival at the laboratory the samples are
processed and loaded onto the automated track
system as per standard laboratory protocols. The
iLFT pathway initially triggers analysis of the locally
agreed liver panel (albumin, bilirubin, ALP, and
ALT), plus gamma-glutamyl transferase (GGT). If
the results of the initial analyses fall within prede-
fined reference ranges, no further analysis is per-
formed and the results are issued to the primary
care physician. However, if results for the initial
measurands exceed these ranges, additional tests
cascade to produce the agreed liver disease etiol-
ogy screen as per the algorithms shown in Fig. 1.
The logic for the iLFT algorithms is programmed
in the LIMS [CliniSys LabCentre v1.13 (CliniSys
Solutions Ltd.)]. The LIMS communicates with the
analysers and AptioVR Automation via middleware
[CentraLinkVR Data Management System v16.0.3.1
(Siemens Healthcare Diagnostics Inc.]. This bi-
directional flow of data allows reflexive addition of
tests from across the laboratory specialties, with
the sample being directed between analyzers in
real-time as required.
iLFT Assays
The automated analyses for the iLFT pathway
are performed on the ADVIAVR 2400 Clinical
Chemistry System [ALT, ALP, total bilirubin, albu-
min, GGT, iron, c-reactive protein (CRP)],
Dimension VistaVR 1500 System (alpha-1 antitryp-
sin, AST, direct bilirubin, ferritin, haptoglobin),
ADVIA CentaurVR XP Immunoassay System (hepati-
tis B surface antigen, hepatitis C IgG antibody) and
SPECIAL REPORT iLFT: intelligent Liver Function Testing
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iLFT requested
Alcohol intake and BMI converted into test results to allow LIMS 
to ‘see’ the information:
Alcohol: ≤14/>14 units per week 
BMI: integer in range ≤26 – ≥35
Initial liver panel performed (ALT, albumin, bilirubin, ALP) + GGT
No 
abnormality
Mild isolated 
hyperbilirubinemia
Mild isolated 
ALP elevation
Any other 
abnormality
No further 
analyses; 
results 
released to 
requestor
Haptoglobin and 
direct bilirubin 
analysis added
If no evidence of 
hemolysis, 
Gilbert syndrome 
URL generated
No further 
analyses; URL 
generated
describing liver 
and bone causes 
of mild ALP 
elevation
Liver etiology screen cascades: AST, ferritin, iron studies, alpha-1 antitrypsin, platelet count, 
hepatitis B and C serology and calculated fibrosis scores (FIB-4 index/NFS) added
Initial virology 
reactive; confirmatory 
testing added
Alpha-1 antitrypsin 
concentration low; 
phenotyping added
Age < 45 years; CRP 
and ceruloplasmin 
added
Appropriate descriptive or diagnostic URL(s) generated based on results of all above analyses
Results reviewed by immunology; ANA and liver antibody screen added where appropriate
AIH, PBC and/or SLE URL generated as per immunology results
Significant 
hyperbilirubinemia
No further 
analyses; urgent 
referral to 
jaundice clinic
advised
Fig. 1. Flow diagram illustrating the basic algorithms used in the iLFT pathway.
iLFT: intelligent Liver Function Testing SPECIAL REPORT
....................................................................................................................
September 2020 | 05:05 | 1090–1100 | JALM 1095
D
ow
nloaded from
 https://academ
ic.oup.com
/jalm
/article/5/5/1090/5904301 by guest on 23 Septem
ber 2020
ADVIAVR 2120i Hematology System (platelet count)
(all Siemens Healthcare Diagnostics Inc.). Where
indicated, liver antibody screening is performed
by indirect immunofluorescence on rat triple block
tissue using QUANTALyserVR 2 (Inova Diagnostics
Inc.) and microscopy. Anti-nuclear antibody (ANA)
testing (also by indirect immunofluorescence) is
performed on HEp-2 slides. Ceruloplasmin and
alpha-1 antitrypsin phenotyping are sent away to
referral centers as per our standard laboratory
protocol.
Reporting of results
The results of the assays are combined with the
clinical details and demographics in the algorithms
to produce one or more URLs that link to PDF files.
These files provide a definitive or descriptive diag-
nosis and a further investigation and/or manage-
ment plan for the primary care physician to follow.
A recommendation as to whether referral to sec-
ondary care is appropriate is clearly stated. Using
centrally-hosted PDF files allows the latest guid-
ance and advice to be incorporated into the plans
in a contemporaneous manner.
The main challenge was reprogramming our
LIMS to allow it to report an active URL, but this
was overcome with the help of Clinisys. The iLFT
report is structured in a way that it can be easily
read in a variety of different clinical software pack-
ages, or via a paper report. A short auto-comment
summarizing the diagnosis and management plan
is always included. Extensive end-to-end testing
was required to cover every foreseeable scenario
including reporting of all of the possible algorithm
outcomes, and how to deal with missing labora-
tory, clinical, or demographic data.
RESULTS
Pilot Trial
A pilot study took place in the Tayside region of
Scotland from September 2015 to November
2016. Six group General Practices (family doctors)
were selected to ensure a mix of urban and
rural patients. Inclusion criteria were people aged
18–75 for whom the GP requested LFTs. Exclusion
criteria were jaundice, preexisting liver disease,
previously known abnormal LFTs, or LFTs being
performed for monitoring of a specific side effect
of a drug or treatment.
A stepped wedge design was used with all six
practices receiving iLFT as an intervention. A con-
trol population was derived from all patients in
the practices who fulfilled the inclusion and exclu-
sion criteria for 6 months prior to the intervention
in each practice.
For all patients requiring LFTs, GPs could
request iLFT instead of standard LFTs, simply by
entering the BMI, diabetes status, and alcohol in-
take of the patient. If the components of the
LFT results were abnormal based on NHS Tayside
limits, the automated cascade of reflex tests was
performed as described above. The report and 1
of 31 management plans were then made avail-
able to the GP in real time for action. The study
team then reviewed each patient’s notes 6
months after the intervention to assess the diag-
nosis recorded by the GP who had received the
management plan from the iLFT result.
There were 490 patients in the control group
and 229 patients in the intervention group. In the
latter group, 64 (27.9%) patients had abnormal
LFTs. GPs were able to ignore or adjust the iLFT di-
agnosis in favor of their own clinical diagnosis. iLFT
supported the GP diagnosis in 67% of cases.
However, the rate of liver disease diagnosis in-
creased by 43% using iLFT (P< 0.0002) compared
with controls. The number of nurse visits and
blood requests did not increase. Referrals to hep-
atology specialist clinics were increased with an
odds ratio of 8.44 (95% CI 1.99–35.73), in keeping
with an increased detection of advanced liver
disease.
A within-trial analysis assessed the cost effec-
tiveness of iLFT. There is an incremental cost per
SPECIAL REPORT iLFT: intelligent Liver Function Testing
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correct diagnosis of £284. However, there is a cost
saving of £3216 per patient lifetime with 0.021
quality-adjusted life year (QALY) gain, confirmed
using a 1000 iteration Monte Carlo probabilistic
analysis.
In a survey, 21 of the 23 GPs involved in the trial
felt that iLFT reduced their workload and were
positive about the project.
Real-World Data
Following the successful trial, iLFT went ‘live’ in
Tayside in August 2018.
Requests were received for 2362 iLFT cascades
in the 1 year from launch. A total of 160 (6.8%)
were rejected due to missing clinical details such
as alcohol history, or because the patient had had
iLFT performed within the past 12months.
Normal LFTs were present in 378 (16%) cases and
thus iLFT did not cascade. There were 1824
(77.2%) requests with at least 1 abnormal liver en-
zyme, resulting in iLFT cascade and 2013 diagnos-
tic outcomes. Patients may have more than 1
diagnostic outcome if, for example, they have high
levels of alcohol intake and also have positive hep-
atitis C virology, which would result in 2 separate
management plans being sent to the GP.
The most common outcome was isolated ALT
elevation without fibrosis (23.5%), followed by
alcohol-related liver disease without fibrosis
(14.7%) and nonalcoholic fatty liver disease with fi-
brosis (9.4%). The frequency of each outcome is
shown in Fig. 2.
iLFT recommended patients be referred to sec-
ondary care in 509 (25.3%) outcomes (of which
393 (77.2%) were for further assessment of fibro-
sis only), with 1504 (74.7%) recommending pri-
mary care management.
CONCLUSIONS
iLFT offers significant benefits to all the special-
ties involved in the diagnosis of liver disease.
A recent survey of 100 local GPs showed that 98%
would recommend iLFT to a colleague. More GPs
continue to adopt the new iLFT test, with uptake
in the Tayside region still showing exponential in-
crease as of January 2020. iLFT also benefits hepa-
tologists because patients referred to clinic
following iLFT already have their liver screen
results and calculated fibrosis scores available,
saving time and clinic venipuncture. Anecdotally,
hepatologists now feel that they are seeing the
right patient group in clinic—those in which they
can offer valuable management, advice, and
follow-up. The pilot data indicate that iLFT is cost-
effective and will therefore benefit the health sys-
tem more widely. Of course, longer-term data col-
lection is required to confirm this. Finally, iLFT
benefits patients in multiple ways: it increases
overall diagnosis, allows diagnosis earlier in the
disease course, and with long-term follow-up is
expected to show some increase in QALYs.
However, the development of the iLFT pathway
has not been without limitations and challenges.
Despite the appropriate rate of secondary care re-
ferral recommended by iLFT, the fact that abnor-
mal LFTs are now being fully investigated in line
with national guidance has led to an increased de-
mand for liver clinic appointments. A significant
proportion of patients who receive a recommen-
dation of secondary care referral do so because
of indeterminate fibrosis scores (those between
the ‘rule out’ and ‘rule in’ thresholds). In this inde-
terminate group we are currently investigating
whether incorporation of the ELF score into the
iLFT algorithm could help further stratify patients
by risk of fibrosis, thus reducing unnecessary re-
ferral. A similar approach has been used by
Srivastava et al. in the Camden and Islington
NAFLD pathway and has been shown to be safe
and effective (21).
It has been challenging to engage with local GPs
at the extent necessary for this study, which is un-
derstandable given the immense pressures on
their time. We have provided education sessions
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locally to help GPs make best use of the pathway,
but are still finding that a significant number are
not requesting iLFT in the target group—i.e., as
the first set of liver tests in a patient with sus-
pected liver disease—and are instead using it as a
follow-up test after an initial set of abnormal LFTs.
More structured education would also help us to
emphasize the importance of the accuracy of the
data they enter (as with almost all laboratory test-
ing, the quality of what is put in increases the use-
fulness of the results generated) and help to
reduce requests with missing data or samples.
Finally, it is important that the requestors under-
stand the limitations of iLFT. Whilst it has been
shown to have high accuracy in referral recom-
mendation and good accuracy in diagnosis, it is
purely algorithm-driven, and as with all laboratory
data, should be interpreted in the clinical context.
The development of the iLFT pathway has re-
quired adaptations to overcome issues as they
have arisen, such as autorejection of incomplete
requests and duplicate request evaluation. Given
this, we now have a slightly more complex collec-
tion of algorithms and logic which could be
streamlined if we were to start the project again.
This experience is invaluable when helping other
laboratories to implement their own version of
the iLFT pathway. We have multiple enquiries
from groups around the world, who are now pro-
gressing with iLFT in their own centers at varying
rates. Barriers to roll-out primarily comprise IT
issues (lack of a standardized LIMS or order com-
munications package), organizational issues in
both laboratory and hepatology services, as well
as the configuration of laboratory automation in
individual sites.
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Fig. 2. Chart demonstrating the frequency of the iLFT outcomes generated by 1824 samples with an ab-
normality in the initial liver tests.
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We believe that the success of iLFT is centered on
its utilization of existing technologies and processes
in a novel way, and on its true multi-disciplinary re-
flexive testing approach. These allow the expertise of
hepatology, clinical biochemistry, virology, immunol-
ogy, and hematology to combine to generate a clear,
practical report that assists GPs to investigate poten-
tial liver disease in line with guidelines. The general
approach used in iLFT, namely the combination of
demographic and clinical information with blood test
results, lends itself to various other clinical problems.
One such avenue is in the investigation, diagnosis,
and management of the various causes of anemia.
iLFT helps to break down the barrier we often
find between clinical and laboratory medicine, and
uses information from both to increase diagnosis
and improve patient outcomes. We have been
proud to receive accolades from leading healthcare
organizations across medicine, including the Royal
College of Physicians (London), Royal College of
Pathologists, and a UNIVANTS of Healthcare
Excellence award. Our health service continues to
require cost-, time- and personnel-efficient
approaches to deal with the ever-increasing work-
load, and intelligent testing pathways such as iLFT
hold the promise of forming part of the solution.
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